Kura Oncology (NASDAQ:KURA) stock slid 7% in post-market trading after the company issued an update on its drug ziftomenib.

Kura (NASDAQ:KURA) reported positive Phase 2 data from a registration-directed trial called KOMET-001 of ziftomenib in patients with relapsed/refractory NPM1-m